2023 Fiscal Year Final Research Report
Role of mesenchymal stem cells in the regulation of neuroblastoma microenvironment
| Project/Area Number |
21K07750
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52050:Embryonic medicine and pediatrics-related
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
山本 暢之 神戸大学, 医学部附属病院, 講師 (20596043)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | 高リスク神経芽腫 / 微小残存病変 / 間葉系幹細胞 / 治療誘発細胞老化 / 細胞老化随伴分泌現象 |
|---|
| Outline of Final Research Achievements |
Although most high-risk neuroblastoma (NB) patients initially respond to therapy and reach remission, more than half of them relapse and develop the therapy-resistance, making long-term survival difficult. This is because residual NB cells left in the body after therapy frequently show different characteristics without genetic mutations. After chemotherapy and radiation therapy, sub-lethally damaged (therapy-induced senescence: TIS) cells are known to increase the secretion of exosomes, cytokines, and other substances (senescence-associated secretory phenotype: SASP). In the present study, we focus on mesenchymal stem cells (MSCs) with high secretory activity and aim to identify and characterize the molecules secreted by SASP from MSCs.
|
| Free Research Field |
小児腫瘍学
|
| Academic Significance and Societal Importance of the Research Achievements |
高リスク神経芽腫は、患者の半数以上が再発して治療抵抗性を示す代表的な難治性小児がんである。再発した高リスク神経芽腫患者の治療抵抗性獲得には、治療後に体内に残存したがん細胞が遺伝子変異を伴わずに異なる形質を示すことが重要で、がん微小環境中の細胞から分泌される因子の同定が必須だと考えられる。そこで本研究では、神経芽腫のがん微小環境の主要な構成細胞で分泌活性の高い間葉系幹細胞(MSC)の役割を明らかにすることを試みた。その成果は、高リスク神経芽腫患者に対する新たな治療法の開発、予後の改善に繋がると期待される。
|
